Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focusing on the development and commercialization of novel therapies that address unmet needs in the treatment of liver and cardiovascular diseases, has reported a significant insider sell according to the latest SEC filings.
Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of the company on April 1, 2024, according to a recent SEC Filing.
James Daly, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 32,489 shares of the company on April 2, 2024, according to a recent SEC Filing.
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research report report published on Thursday. Several other brokerages also recently commented on MDGL. UBS Group raised their target price on Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a buy rating in a research note on […]
Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.